PAF (C16)
(Synonyms: Β-乙酰基-Γ-O-十六烷基-L-Α-卵磷脂,Platelet-activating Factor C-16) 目录号 : GC14535PAF(C16)是一种膜源磷脂，也是血小板活化因子和PAF G蛋白偶联受体(PAFR)的配体。
Cas No.:74389-68-7
Sample solution is provided at 25 µL, 10mM.
PAF(C16) is a membrane-derived phospholipid, It is also a platelet activating factor and a ligand for PAF G protein-coupled receptor (PAFR). PAF(C16) is a potent MAPK and MEK/ERK activator. PAF(C16) can induce cell exosmosis in a dose-dependent manner and improve vascular permeability. PAF(C16) inhibits Caspase-dependent cell apoptosis by activating PAFR and has anti-apoptotic effect[1-4].
PAF(C16) (10, 25, 50, and 100 μg/ml; 2 h) inhibits M. smegmatis and M. bovis BCG growth in a dose-dependent manner[2]. PAF(C16) (10 nM; 24 h) can destroy the decreased levels of IL-25 and IL-33 in cells caused by 5α-DHT [5]. 500 nM PAF(C16) increased the numbers of phenotypic Haematopoietic stem/progenitor cell (HSPC) and induced cell cycling of HSPC[6].
PAF(C16) (5 mg/kg; orally administrated every 3 days) significantly inhibited the effect of 5α-DHT on airway hyperreactivity (AHR) [4]. PAF(C16) (0.5-10 ng/kg) given as a bolus into the renal arterial circulation of pentobarbital sodium-anesthetized male Wistar rats caused systemic hypotension and produced a dose-dependent increase in renal blood flow [7].
References:
[1]. Vadas, P, Perelman, B, et,al. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J. Allergy Clin. Immunol. 131, 144–149. doi: 10.1016/j.jaci.2012.08.016
[2]. Riaz MS, Kaur A, et,al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903. doi: 10.3389/fmicb.2018.01903. PMID: 30258409; PMCID: PMC6143801.
[3]. Ryan SD, Harris CS, et,al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8. doi: 10.1194/jlr.M800263-JLR200. Epub 2008 Jun 12. PMID: 18550892.
[4]. Bögershausen N, Tsai IC, et,al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99. doi: 10.1172/JCI80102. Epub 2015 Aug 17. PMID: 26280580; PMCID: PMC4588287.
[5]. Xia T, Ma J, et,al. Androgen receptor suppresses inflammatory response of airway epithelial cells in allergic asthma through MAPK1 and MAPK14. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221121320. doi: 10.1177/09603271221121320. PMID: 35982617.
[6]. Sun Q, Zhou Y, et,al. MEK1 activation enhances the ex vivo proliferation of haematopoietic stem/progenitor cell. Cell Biochem Funct. 2022 Jan;40(1):79-89. doi: 10.1002/cbf.3677. Epub 2021 Dec 2. PMID: 34855220.
[7]. Handa RK, Strandhoy JW, et,al. Platelet-activating factor is a renal vasodilator in the anesthetized rat. Am J Physiol. 1990 Jun;258(6 Pt 2):F1504-9. doi: 10.1152/ajprenal.1990.258.6.F1504. PMID: 2360650.
PAF(C16)是一种膜源磷脂，也是血小板活化因子和PAF G蛋白偶联受体(PAFR)的配体。PAF(C16)是一种有效的MAPK和MEK/ERK激活剂。PAF(C16)能以剂量依赖的方式诱导细胞外渗，改善血管通透性。PAF(C16)通过激活PAFR抑制caspase依赖性细胞凋亡，具有抗凋亡作用[1-4]。
PAF(C16) (10, 25, 50, and 100 μg/ml; 2 h)以剂量依赖的方式抑制耻垢分枝杆菌和牛分枝杆菌的生长[1]。PAF(C16) (10 nM ; 24 h)可破坏5α-DHT引起的细胞IL-25、IL-33水平下降[5]。500 nM PAF(C16)可增加表型造血干细胞/祖细胞(HSPC)的数量，并诱导HSPC的细胞周期[6]。
PAF(C16) (5 mg/kg; orally administrated every 3 days)显著抑制5α-DHT对气道高反应性(AHR)的影响[4]。给麻醉的雄性Wistar大鼠肾动脉循环注射PAF(C16) (0.5-10 ng/kg)可引起全体性低血压，并使肾血流量呈剂量依赖性增加[7]。
|
Cell experiment [1]: |
|
|
Cell lines |
BEAS-2B cells |
|
Preparation method |
Cells were divided into five groups, including control group, TGF-β1 treated group, TGF-β1 plus 5α-DHT treated group, TGF-β1 plus chicanine (a p38 MAPK and ERK1/2 inhibitor) treated group, TGF-β1 plus 5α-DHT and PAF(C16) treated group. The treated concentration and time of drugs were 1 nM 5α-DHT for 24 h, 50 μM chicanine for 24 h, 10 nM PAF(C16) for 24 h. Chicanine and PAF(C16) were dissolved in 2 % ethanol. |
|
Reaction Conditions |
10 nM; 24 h |
|
Applications |
PAF(C16) can destroy the decreased levels of IL-25 and IL-33 in cells caused by 5α-DHT. |
|
Animal experiment [1]: |
|
|
Animal models |
Female Wistar rats (220 ± 30 g) |
|
Preparation method |
The rats were randomly divided into six groups: control group, ovalbumin(OVA) model group (OVA), vehicle treated group (OVA + vehicle), 0.5 mg/kg 5α-DHT treated group (OVA + 5α-DHT), 15 mg/kg chicanine treated group (OVA + chicanine), 5α-DHT and 5 mg/kg PAF(C16) treated group (OVA +5α-DHT + PAF(C16)). During experiments, rats were orally administrated with vehicle or 5α-DHT or chicanine or 5α-DHT plus PAF(C16) every 3 days. |
|
Dosage form |
5 mg/kg; orally administrated every 3 days |
|
Applications |
PAF(C16) significantly inhibited the effect of 5α-DHT on airway hyperreactivity (AHR). |
|
References: [1]. Xia T, Ma J,et,al. Androgen receptor suppresses inflammatory response of airway epithelial cells in allergic asthma through MAPK1 and MAPK14. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221121320. doi: 10.1177/09603271221121320. PMID: 35982617. |
|
| Cas No. | 74389-68-7 | SDF | |
| 别名 | Β-乙酰基-Γ-O-十六烷基-L-Α-卵磷脂,Platelet-activating Factor C-16 | ||
| 化学名 | (R)-2-acetoxy-3-(hexadecyloxy)propyl (2-(trimethylammonio)ethyl) phosphate | ||
| Canonical SMILES | [O-][P@@](OCC[N+](C)(C)C)(OC[C@@H](COCCCCCCCCCCCCCCCC)OC(C)=O)=O | ||
| 分子式 | C26H54NO7P | 分子量 | 523.68 |
| 溶解度 | 10 mg/ml in DMF,10 mg/ml in DMSO,10 mg/ml in Ethanol,PBS (pH 7.2): 25 mg/ml,30 mg/ml in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8191 mL |
| 10 mM | 0.191 mL | 0.9548 mL | 1.9096 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
